WO2008048685A3 - Ox40 aptamers - Google Patents

Ox40 aptamers Download PDF

Info

Publication number
WO2008048685A3
WO2008048685A3 PCT/US2007/022357 US2007022357W WO2008048685A3 WO 2008048685 A3 WO2008048685 A3 WO 2008048685A3 US 2007022357 W US2007022357 W US 2007022357W WO 2008048685 A3 WO2008048685 A3 WO 2008048685A3
Authority
WO
WIPO (PCT)
Prior art keywords
aptamers
relates
compositions
methods
same
Prior art date
Application number
PCT/US2007/022357
Other languages
French (fr)
Other versions
WO2008048685A9 (en
WO2008048685A2 (en
Inventor
Bruce A Sullenger
Claudia Dollins
Eli Gilboa
Original Assignee
Univ Duke
Bruce A Sullenger
Claudia Dollins
Eli Gilboa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Bruce A Sullenger, Claudia Dollins, Eli Gilboa filed Critical Univ Duke
Publication of WO2008048685A2 publication Critical patent/WO2008048685A2/en
Publication of WO2008048685A9 publication Critical patent/WO2008048685A9/en
Publication of WO2008048685A3 publication Critical patent/WO2008048685A3/en
Priority to US12/385,797 priority Critical patent/US20100076060A1/en
Priority to US13/137,174 priority patent/US20120083521A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates, in general, to aptamers and, in particular, the invention relates to aptamers capable of activating transcription factors, to compositions comprising such aptamers and to methods of using same. The invention further relates to aptamers capable of binding to and activating OX40, to compositions comprising such aptamers and to methods of using same.
PCT/US2007/022357 2005-09-15 2007-10-19 Ox40 aptamers WO2008048685A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/385,797 US20100076060A1 (en) 2005-09-15 2009-04-20 Aptamers as agonists
US13/137,174 US20120083521A1 (en) 2005-09-15 2011-07-25 Aptamers as agonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85270506P 2006-10-19 2006-10-19
US60/852,705 2006-10-19
US97758907P 2007-10-04 2007-10-04
US60/977,589 2007-10-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/036090 Continuation-In-Part WO2007035518A2 (en) 2005-09-15 2006-09-15 Aptamers as agonists
US6659808A Continuation-In-Part 2005-09-15 2008-10-02

Publications (3)

Publication Number Publication Date
WO2008048685A2 WO2008048685A2 (en) 2008-04-24
WO2008048685A9 WO2008048685A9 (en) 2008-07-03
WO2008048685A3 true WO2008048685A3 (en) 2009-04-09

Family

ID=39314686

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/022357 WO2008048685A2 (en) 2005-09-15 2007-10-19 Ox40 aptamers

Country Status (1)

Country Link
WO (1) WO2008048685A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8685937B2 (en) 2008-08-09 2014-04-01 University Of Iowa Research Foundation Nucleic acid aptamers
US10307472B2 (en) 2014-03-12 2019-06-04 Curevac Ag Combination of vaccination and OX40 agonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406681B1 (en) * 2000-08-21 2002-06-18 Aeropharm Technology, Inc. Method of treating a systemic disease
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US20040081648A1 (en) * 2002-08-27 2004-04-29 Afeyan Noubar B. Adzymes and uses thereof
WO2004081021A2 (en) * 2003-03-12 2004-09-23 Duke University Oligonucleotide mimetics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6406681B1 (en) * 2000-08-21 2002-06-18 Aeropharm Technology, Inc. Method of treating a systemic disease
US20040081648A1 (en) * 2002-08-27 2004-04-29 Afeyan Noubar B. Adzymes and uses thereof
WO2004081021A2 (en) * 2003-03-12 2004-09-23 Duke University Oligonucleotide mimetics

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GILBOA ET AL.: "teach cancer immunotherapy by stimulation of OX40 using mRNA transfected dendritic cells.", IMMUNOLOGICAL REVIEWS., vol. 199, 2004, pages 251 - 263 *
SANTULLI-MAROTTO ET AL.: "suggest nucleic acid aptamers that target OX40", CANCER RESEARCH., vol. 63, 1 November 2003 (2003-11-01), pages 7483 - 7489 *
VIEWEG ET AL.: "teach Ox40 stimulates the proliferation of Th1 and Th2 CD3+ T cells. pg 329-341", SPRINGER SEMIN IMMUN., vol. 26, 2005 *

Also Published As

Publication number Publication date
WO2008048685A9 (en) 2008-07-03
WO2008048685A2 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
HK1211040A1 (en) New albumin binding compositions, methods and uses
WO2010065969A8 (en) Sparc binding scfcs
HK1204656A1 (en) Methods and compositions involving mirna and mirna inhibitor molecules mirna mirna
IL230759A0 (en) Substituted acylanilide, composition comprising it and uses thereof
GB0601143D0 (en) Uses, methods and compositions
AU2007222991A8 (en) Compositions and methods based on peptide binding profiling
PL396375A1 (en) Compositions comprising arylpyrazole and / or formamidine, methods and uses thereof
WO2008131150A3 (en) New urethane (meth)acrylates and their use in curable coating compositions
WO2008002893A8 (en) Anti-amyloid antibodies, compositions, methods and uses
WO2009039307A3 (en) Hydrogels and methods for producing and using the same
WO2010045388A3 (en) Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
WO2007095347A3 (en) Methods and compositions related to ghs-r antagonists
WO2008116220A3 (en) Methods and compositions related to riboswitches that control alternative splicing
WO2007144779A3 (en) Compositions comprising porphyra and methods of making and using thereof
WO2010066639A3 (en) Skin lightening compositions with acetylcholinesterase inhibitors
WO2007127506A8 (en) Anti-ephrinb2 antibodies and methods using same
AU2007291030A8 (en) Novel compositions and methods
GB0719367D0 (en) Transcription factor decoys, compositions and methods
WO2009137605A3 (en) AFFINITY MATURED CRIg VARIANTS
WO2008048685A3 (en) Ox40 aptamers
WO2009106258A8 (en) Diflufenican-containing herbicidal combinations
WO2009088939A3 (en) Compositions and methods for treating neurodegenerative diseases
WO2007133571A3 (en) Methods and compositions related to tr4
WO2007035755A3 (en) Methods of treating hematological malignancies
WO2007035518A3 (en) Aptamers as agonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867253

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07867253

Country of ref document: EP

Kind code of ref document: A2